RPRX
Royalty Pharma Plc
57.70$
-1.5%
vs. previous close
Closing price · As of: Sep 23, 2026
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 51.7% | 12.8% | 102.8% | 1.1% | 40.3% | 27.6% | 22.4% | 35.2% | 0.2% | 0.2% | 0.2% | 39.8% | 10.7% | |
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 99.8% | 60.2% | 89.4% | |
| 9.4% | 0.1% | 0.1% | 0.1% | 0.1% | 0.1% | 8.9% | 51.9% | 8.3% | 8.2% | 6.3% | 14.5% | 9.4% | |
| 10.7% | 9.9% | 10.2% | 10.2% | 10.0% | 11.4% | 19.5% | 31.1% | 19.5% | 26.4% | 25.2% | 24.0% | 23.8% | |
| 71.8% | -2.8% | 113.0% | 49.8% | -30.2% | 39.1% | 6.0% | 63.7% | 29.9% | 37.6% | -0.5% | 40.5% | 27.0% | |
| 28.2% | 102.8% | -13.0% | 50.2% | 130.2% | 60.9% | 94.0% | 36.3% | 70.1% | 62.4% | 100.3% | 19.7% | 62.3% | |
| 8.6% | 7.9% | 7.8% | 9.1% | 11.8% | 11.1% | 11.5% | 11.9% | 13.1% | 15.1% | 14.9% | 13.9% | 14.2% | |
| 22.8% | 120.4% | -0.8% | 36.2% | 142.8% | 56.3% | 76.3% | 15.7% | 72.9% | 57.2% | 74.3% | 12.1% | 53.2% | |
| 9.3% | 37.4% | -1.6% | 17.2% | 46.5% | 21.2% | – | 10.4% | 25.6% | 22.8% | 27.4% | – | – | |
| 13.4% | 82.9% | 0.8% | 19.0% | 96.3% | 35.1% | 41.9% | 5.2% | 47.3% | 34.4% | 46.8% | 2.7% | 32.1% | |
| 31.3% | 128.3% | 7.0% | 45.3% | 154.6% | 67.4% | 87.8% | 27.5% | 86.2% | 72.6% | 89.3% | 26.2% | 67.7% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: September 23, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.